The abstract is read at the publisher; the summary is JClub's.
First-line IO-based combination regimens for metastatic clear-cell RCC show no OS benefit in IMDC favourable patients (pooled HR 0.98), but the strongest benefit in IMDC poor patients (pooled HR 0.51).
- Why it matters: Clinicians need to know which prognostic groups gain from first-line checkpoint inhibitor combinations, because OS effects vary and prior evidence has not quantified this heterogeneity.
- What they did: A preregistered IPD meta-analysis of four randomized trials (3320 patients; sunitinib control; mature OS as of Nov 2023) pooled OS using fixed-effects models, stratifying by IMDC and, for IPD, CPI2.
- The result: PD-L1 expression at 5% significantly modified treatment effect, and OS benefit was strongest in poor prognosis subgroups, with CPI2 dRMST of 7.36 months (95% CI 4.56 to 10.17).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.